Robotic Surgery: Beyond da Vinci, Where Are the Next Opportunities?

Robotic surgery is moving into a more competitive phase. Established companies are expanding their platforms, new systems are entering the market, and hospitals are evaluating how robotic technology can improve surgical capacity without adding unsustainable costs.

Intuitive Surgical reported 11,106 da Vinci systems installed worldwide at the end of 2025, up 12% year over year. Its systems supported approximately 3.15 million da Vinci procedures in 2025, an 18% increase from 2024. The company placed 1,721 systems during the year, including 870 next-generation da Vinci 5 systems.

For manufacturers and investors, the opportunity extends beyond developing another surgical robot. Instruments, workflow software, training, maintenance, and specialised surgical applications may offer more focused entry points.

Download Sample Report: https://www.towardshealthcare.com/download-sample/5502 

Which Companies Are Challenging the Established Leader?

Johnson & Johnson received FDA De Novo authorization for OTTAVA on July 21, 2026, for specified upper-abdominal general surgery procedures. This introduces another authorised platform into the US competitive landscape.

However, regulatory authorisation does not automatically translate into hospital purchases. Each manufacturer must demonstrate clinical suitability, service reliability, training support, and a sustainable economic case.

The Market Gap: Hospitals Need Better Economics

Intuitive's 2025 financial results illustrate the commercial importance of recurring products. Its instruments and accessories revenue increased 19% to approximately $6.02 billion, while systems revenue rose 26% to approximately $2.47 billion.

This highlights a critical business opportunity: revenue is generated not only when a hospital buys a robot, but also when it uses the platform for procedures and purchases the required instruments and accessories.

Three gaps deserve attention:

• High ownership costs: Hospitals must account for acquisition or leasing, maintenance, instruments, training, and operating-room requirements.

• Underutilised systems: Hospitals need sufficient procedure volumes, trained staff, and efficient scheduling to justify their investment.

• Limited access to specialised support: Training, maintenance, technical service, and integration with existing hospital workflows can influence purchasing decisions.

These are potential commercial opportunities, not proof that every hospital faces the same problem. Manufacturers should validate demand with individual buyers.

Where Can New Manufacturers Enter?

Competing directly with established robotic platforms requires substantial engineering, clinical validation, regulatory investment, and service infrastructure. A focused product strategy may offer a more practical starting point.

For companies entering this sector, the first objective should be to solve one clearly defined hospital problem. A validated product, clinical partner, and measurable business case can provide a stronger foundation than attempting to build a complete robotic platform immediately.

What Should Investors Monitor?

Investors should evaluate procedure growth, installed systems, system utilisation, recurring instrument revenue, regulatory progress, and the manufacturer's ability to establish service infrastructure.

They should also distinguish between announced partnerships, regulatory approvals, actual system placements, and sustained clinical adoption. These represent different stages of commercial progress.

The strongest opportunities may emerge in products that help hospitals use existing systems more efficiently, reduce operational barriers, or extend robotic capabilities into clearly defined clinical applications.

How Towards Healthcare Supports Commercial Decisions

Towards Healthcare offers a Robotic Surgery Master Dataset, Competitive Quadrant, and dedicated dashboard to help manufacturers, investors, and healthcare organisations assess the competitive landscape.

These resources can support:

• Competitive benchmarking: Compare companies, robotic platforms, product portfolios, and strategic positioning.

• Product intelligence: Track system developments, regulatory milestones, partnerships, and technology launches.

• Buyer identification: Identify hospitals and healthcare organisations for account-level research and sales planning.

• Opportunity assessment: Examine adoption patterns, potential application gaps, and competitive positioning before entering a segment.

The key question is not simply which company will challenge da Vinci. It is which technology or service can solve a measurable hospital problem and build a commercially sustainable position in robotic surgery.

Explore the robotic surgery company landscape and competitive intelligence to assess potential competitors, product opportunities, and prospective buyers.

About Us

Healthcare WebWire is part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium